Diabetic Med:2型糖尿病延迟临床诊断的患病率和预测因素?

2018-12-28 MedSci MedSci原创

近日,国际杂志 《Diabetic Med》上在线发表一项关于2型糖尿病延迟临床诊断的患病率和预测因素:纵向队列的研究。研究目的在于检查HbA1c值升高的成人中未确诊的2型糖尿病的患病率和人群水平预测因子。 研究人员于2014年1月和2015年12月之间确定了HbA 1C(HbA 1C ≥48毫摩尔/摩尔;≥6.5%)首次升高的无糖尿病成人,并根据患者1年后的2型糖尿病诊断情况进行分类。采

近日,国际杂志 《Diabetic Med》上在线发表一项关于2糖尿病延迟临床诊断的患病率和预测因素:纵向队列的研究。研究目的在于检查HbA1c值升高的成人中未确诊的2糖尿病的患病率和人群水平预测因子。

研究人员于20141月和201512月之间确定了HbA 1CHbA 1C 48毫摩尔/摩尔;6.5%)首次升高的无糖尿病成人,并根据患者1年后的2型糖尿病诊断情况进行分类。采用多级建模技术分析个体人口统计学,临床和利用特征与剩余未确诊的关联。研究人员量化了诊断和未确诊个体之间早期2型糖尿病护理的差异。

研究发现,在首次HbA 1c升高的18 356名成年人中,30.2%在1年后仍未确诊为2型糖尿病。HbA1c值较低的个体[校正后比值比(aOR5.95,95%置信区间(CI5.21-6.7848<53 mmol / mol6.5%至7.0%); 参照53<64 mmol / mol7.0%至<8.0%),≥70岁(aOR 1.40,95CI 1.24-1.59;参考50-59岁),并且曾有过前期糖尿病诊断( aOR 1.35,95CI 1.24-1.47;参考没有前驱糖尿病)会增加了未确诊的几率。在校正年龄,种族和HbA 1c后,剩余未确诊与二甲双胍开始治疗的可能性较低相关(aOR 0.06,95CI 0.05-0.07)。

研究认为,几乎三分之一的HbA 1c值升高的成年人在1年内未被诊断出患有2型糖尿病。反过来,未确诊的2型糖尿病与早期护理的差异有关。利用电子健康记录促进早期诊断的策略可能有助于减少延迟诊断并允许早期干预以实现改善结果的目标。

原始出处:

A. GopalanP. MishraS. E. Alexeeffet al. Prevalence and predictors of delayed clinical diagnosis of Type 2 diabetes: a longitudinal cohort study

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1760967, encodeId=e6c81e6096701, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Mar 23 06:44:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638936, encodeId=8de01638936f1, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jun 18 07:44:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970684, encodeId=2bf819e0684fc, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Thu May 30 11:44:00 CST 2019, time=2019-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250593, encodeId=269512505933a, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sun Dec 30 00:44:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264310, encodeId=b8a512643105d, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sun Dec 30 00:44:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543291, encodeId=05b115432914d, content=<a href='/topic/show?id=08ef230191c' target=_blank style='color:#2F92EE;'>#临床诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23019, encryptionId=08ef230191c, topicName=临床诊断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c35213562602, createdName=ms5906905816781247, createdTime=Sun Dec 30 00:44:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609418, encodeId=da48160941805, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Dec 30 00:44:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042162, encodeId=346310421628b, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Dec 28 12:44:00 CST 2018, time=2018-12-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1760967, encodeId=e6c81e6096701, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Mar 23 06:44:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638936, encodeId=8de01638936f1, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jun 18 07:44:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970684, encodeId=2bf819e0684fc, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Thu May 30 11:44:00 CST 2019, time=2019-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250593, encodeId=269512505933a, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sun Dec 30 00:44:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264310, encodeId=b8a512643105d, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sun Dec 30 00:44:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543291, encodeId=05b115432914d, content=<a href='/topic/show?id=08ef230191c' target=_blank style='color:#2F92EE;'>#临床诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23019, encryptionId=08ef230191c, topicName=临床诊断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c35213562602, createdName=ms5906905816781247, createdTime=Sun Dec 30 00:44:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609418, encodeId=da48160941805, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Dec 30 00:44:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042162, encodeId=346310421628b, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Dec 28 12:44:00 CST 2018, time=2018-12-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1760967, encodeId=e6c81e6096701, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Mar 23 06:44:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638936, encodeId=8de01638936f1, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jun 18 07:44:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970684, encodeId=2bf819e0684fc, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Thu May 30 11:44:00 CST 2019, time=2019-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250593, encodeId=269512505933a, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sun Dec 30 00:44:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264310, encodeId=b8a512643105d, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sun Dec 30 00:44:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543291, encodeId=05b115432914d, content=<a href='/topic/show?id=08ef230191c' target=_blank style='color:#2F92EE;'>#临床诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23019, encryptionId=08ef230191c, topicName=临床诊断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c35213562602, createdName=ms5906905816781247, createdTime=Sun Dec 30 00:44:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609418, encodeId=da48160941805, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Dec 30 00:44:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042162, encodeId=346310421628b, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Dec 28 12:44:00 CST 2018, time=2018-12-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1760967, encodeId=e6c81e6096701, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Mar 23 06:44:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638936, encodeId=8de01638936f1, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jun 18 07:44:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970684, encodeId=2bf819e0684fc, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Thu May 30 11:44:00 CST 2019, time=2019-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250593, encodeId=269512505933a, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sun Dec 30 00:44:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264310, encodeId=b8a512643105d, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sun Dec 30 00:44:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543291, encodeId=05b115432914d, content=<a href='/topic/show?id=08ef230191c' target=_blank style='color:#2F92EE;'>#临床诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23019, encryptionId=08ef230191c, topicName=临床诊断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c35213562602, createdName=ms5906905816781247, createdTime=Sun Dec 30 00:44:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609418, encodeId=da48160941805, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Dec 30 00:44:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042162, encodeId=346310421628b, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Dec 28 12:44:00 CST 2018, time=2018-12-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1760967, encodeId=e6c81e6096701, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Mar 23 06:44:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638936, encodeId=8de01638936f1, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jun 18 07:44:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970684, encodeId=2bf819e0684fc, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Thu May 30 11:44:00 CST 2019, time=2019-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250593, encodeId=269512505933a, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sun Dec 30 00:44:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264310, encodeId=b8a512643105d, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sun Dec 30 00:44:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543291, encodeId=05b115432914d, content=<a href='/topic/show?id=08ef230191c' target=_blank style='color:#2F92EE;'>#临床诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23019, encryptionId=08ef230191c, topicName=临床诊断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c35213562602, createdName=ms5906905816781247, createdTime=Sun Dec 30 00:44:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609418, encodeId=da48160941805, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Dec 30 00:44:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042162, encodeId=346310421628b, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Dec 28 12:44:00 CST 2018, time=2018-12-28, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1760967, encodeId=e6c81e6096701, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Mar 23 06:44:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638936, encodeId=8de01638936f1, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jun 18 07:44:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970684, encodeId=2bf819e0684fc, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Thu May 30 11:44:00 CST 2019, time=2019-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250593, encodeId=269512505933a, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sun Dec 30 00:44:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264310, encodeId=b8a512643105d, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sun Dec 30 00:44:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543291, encodeId=05b115432914d, content=<a href='/topic/show?id=08ef230191c' target=_blank style='color:#2F92EE;'>#临床诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23019, encryptionId=08ef230191c, topicName=临床诊断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c35213562602, createdName=ms5906905816781247, createdTime=Sun Dec 30 00:44:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609418, encodeId=da48160941805, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Dec 30 00:44:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042162, encodeId=346310421628b, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Dec 28 12:44:00 CST 2018, time=2018-12-28, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1760967, encodeId=e6c81e6096701, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Mar 23 06:44:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638936, encodeId=8de01638936f1, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jun 18 07:44:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970684, encodeId=2bf819e0684fc, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Thu May 30 11:44:00 CST 2019, time=2019-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250593, encodeId=269512505933a, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sun Dec 30 00:44:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264310, encodeId=b8a512643105d, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sun Dec 30 00:44:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543291, encodeId=05b115432914d, content=<a href='/topic/show?id=08ef230191c' target=_blank style='color:#2F92EE;'>#临床诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23019, encryptionId=08ef230191c, topicName=临床诊断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c35213562602, createdName=ms5906905816781247, createdTime=Sun Dec 30 00:44:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609418, encodeId=da48160941805, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Dec 30 00:44:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042162, encodeId=346310421628b, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Dec 28 12:44:00 CST 2018, time=2018-12-28, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1760967, encodeId=e6c81e6096701, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Mar 23 06:44:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638936, encodeId=8de01638936f1, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jun 18 07:44:00 CST 2019, time=2019-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970684, encodeId=2bf819e0684fc, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Thu May 30 11:44:00 CST 2019, time=2019-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250593, encodeId=269512505933a, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sun Dec 30 00:44:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264310, encodeId=b8a512643105d, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sun Dec 30 00:44:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543291, encodeId=05b115432914d, content=<a href='/topic/show?id=08ef230191c' target=_blank style='color:#2F92EE;'>#临床诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23019, encryptionId=08ef230191c, topicName=临床诊断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c35213562602, createdName=ms5906905816781247, createdTime=Sun Dec 30 00:44:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609418, encodeId=da48160941805, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Dec 30 00:44:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042162, encodeId=346310421628b, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Dec 28 12:44:00 CST 2018, time=2018-12-28, status=1, ipAttribution=)]
    2018-12-28 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

Diabetic Med:利拉鲁肽在2型糖尿病中的临床疗效的个体间差异?

近日,国际杂志 《Diabetic Med》上在线发表一项在西班牙进行的关于利拉鲁肽在2型糖尿病中的临床疗效的个体间差异的现实世界的回顾性研究。 研究在实际临床环境中利拉鲁肽治疗24个月后临床变量(HbA 1c,体重,血脂和血压)的反应,并通过使用广义加性混合模型(GAMM)处理,描述利拉鲁肽引起HbA 1c的变化和体重减轻。 研究人员纳入了年龄≥18岁且患有2型糖尿病的人(在201

Diabetic Med:勃起功能障碍的诊断可用于改善2型糖尿病的筛查?

近日,国际杂志 《Diabetic Med》上在线发表一项关于勃起功能障碍的诊断可用于改善2型糖尿病的筛查的研究。评估四种未确诊的2型糖尿病风险评分对勃起功能障碍的诊断准确性。 这是一项基于人群的横断面研究。2型糖尿病根据口服葡萄糖耐量试验和自我报告的医生诊断确定。勃起功能障碍的定义是根据问题的答案,“你在过去的6个月内难以勃起吗?” (是/否)。使用的风险评分包括FINDRISC,LA-

JAMA Network Open:胰岛素、磺脲类药物增加糖尿病心血管风险

美国一项新的真实世界研究表明,使用胰岛素或磺脲类药物作为成人2型糖尿病(T2DM)患者的二线治疗会增加心血管风险,而使用新型降糖药物则不然。

KIDNEY INT:血浆内皮抑素可预测2型糖尿病患者的肾脏结局

由此可见,血浆内皮抑素与eGFR正常的2型糖尿病患者肾脏结局密切相关,并与传统预测因子相比风险区分能力得到了有效改善。

DIABETOLOGIA:2型糖尿病患者因心力衰竭住院的风险过高

2型糖尿病是心力衰竭的既定的风险因素,但目前仍缺乏相关的年龄特异性数据。本研究的目的是与来自一般人群的年龄和性别匹配的对照个体进行比较,确定基于年龄,血糖控制和肾功能的心力衰竭的过度风险。 研究人员将1998 - 2012年瑞典国家糖尿病登记处(n  = 266,305)登记的2型糖尿病患者与未患糖尿病的年龄,性别和县匹配对照组进行比较(n  = 1,323,504),随

DIABETOLOGIA:降低药物治疗和非药物治疗2型糖尿病的发病率?

在这项挪威全国性队列研究中,研究人员将来自国家登记处的数据与前瞻性收集的糖尿病药物和糖尿病诊断数据联系起来,根据治疗类型,性别,年龄,文化程度和出生地点分析了2009年至2014年2型糖尿病发病率和患病率的趋势。这些数据适用于挪威30至89岁(> 320万人)的所有居民。 结果显示,在2009年至2014年的15,463,691个人年的随访期间,研究人员共确定了75,496名患有新发2